A5060170484- Colorectal Cancer Treatments and Studies
- Testicular diseases and treatments
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Urologic and reproductive health conditions
- Colorectal and Anal Carcinomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Sexual Differentiation and Disorders
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Venous Thromboembolism Diagnosis and Management
- Genital Health and Disease
- Cancer, Lipids, and Metabolism
- Multiple and Secondary Primary Cancers
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cardiac tumors and thrombi
- Glioma Diagnosis and Treatment
Hospital Universitari i Politècnic La Fe
2016-2025
Instituto de Investigación Biomédica de Málaga
2016-2020
Spanish Oncology Genitourinary Group
2020
Leitat Technological Center
1995-2019
University of St. Gallen
2017
St Olav's University Hospital
2017
Spanish Society of Hematology and Hemotherapy
2017
Hospital Clínico Universitario Lozano Blesa
2005-2016
Institut Català d'Oncologia
2001-2016
Hospital de Sant Pau
2005-2016
Purpose This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence KRAS mutation status investigated. Patients Methods received (400 mg/m 2 initial dose followed by 250 /wk thereafter) plus (oxaliplatin 85 on day 1, leucovorin 200 a 400 bolus 600 infusion during 22 hours days 1 2; n = 169)...
PURPOSE The optimal therapeutic sequence of the adjuvant chemotherapy component preoperative chemoradiotherapy (CRT) for patients with locally advanced rectal cancer is controversial. Induction before CRT may be associated better efficacy and compliance. PATIENTS AND METHODS A total 108 were randomly assigned to arm A-preoperative capecitabine, oxaliplatin, concurrent radiation followed by surgery four cycles postoperative capecitabine oxaliplatin (CAPOX)-or B-induction CAPOX surgery....
In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings 2003 (Essen, Germany) 2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. consensus diagnosis treatment germ-cell cancer: a report Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399; S, Beyer J, R second meeting group (EGCCCG): part I. Eur Urol 2008; 53: 478-496; II. 497-513]. A panel 56 60...
The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held 3-5 November 2016 in Paris, France. included a multidisciplinary panel of 36 leading experts the diagnosis and treatment (34 members attended conference; an additional two [CB K-PD] participated all preparatory work subsequent manuscript development). aim to develop detailed recommendations topics relating that are not covered detail current ESMO Clinical Practice Guidelines (CPGs) where...
To assess the value of postsurgery chemotherapy in patients with disseminated nonseminomatous germ-cell tumors (NSGCTs) and viable residual disease after first-line cisplatin-based chemotherapy.The outcome 238 was reviewed. Tumor markers had normalized all before resection. A multivariate analysis survival performed on 146 patients.The 5-year progression-free (PFS) rate 64% overall (OS) 73%. Three factors were independently associated both PFS OS: complete resection (P <.001), < 10%...
The aim of this phase III trial was to compare the efficacy and safety capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC).A total 348 patients were randomly assigned receive XELOX (oral 1,000 mg/m2 bid 14 days 130 on day 1 every 3 weeks) or FUOX (continuous-infusion FU 2,250 during 48 hours 1, 8, 15, 22, 29, 36 85 29 6 weeks).There no significant differences...
To assess the efficacy of a risk-adapted treatment policy for patients with stage I seminoma by using universally accepted risk criteria.Between 1999 and 2003, 314 clinical after orchiectomy were prospectively included. One hundred (31.8%) presented no factors managed surveillance. In contrast, 131 (41.7%) had tumors larger than 4 cm, 33 (10.5%) rete testis involvement, 50 (15.9%) both factors. All latter received two courses adjuvant carboplatin.Chemotherapy was well tolerated, as only 17...
Purpose To confirm the efficacy of a risk-adapted treatment approach for patients with clinical stage I seminoma. The aim was to reduce both risk relapse and proportion receiving adjuvant chemotherapy while maintaining high cure rate. Patients Methods From 2004 2008, 227 were included after orchiectomy in multicenter study. Eighty-four (37%) presented no local factors, 44 (19%) had tumors larger than 4 cm, 25 (11%) rete testis involvement, 74 (33%) criteria. Only latter group received two...
PURPOSE EXONERATE (EXOsome and cell-free micro-RNAs of anti-EGFR ResistAnce) was an open-label, biomarker interventional study designed to develop, test, validate a liquid biopsy predictive progression-free survival (PFS), overall (OS), objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients with newly diagnosed RAS-WT, chemotherapy-naïve mCRC, both right- left-sided, were enrolled 2-nationwide trials receive...
Chemical pleurodesis is an effective treatment of malignant pleural effusions, but indications must be individualised to optimise its results. The aim the present study was investigate relationship various prognostic features with both response rate and probability patient survival. A non-concurrent cohort carried out in which 120 evaluable patients effusion underwent pleurodesis. Lung (40%), breast (26.6%), unknown primary site (12.5%) carcinomas were most frequent neoplasms. Clinical data...
To assess the long-term efficacy and toxicity of front-line cisplatin-based chemotherapy in patients with stage IIA or IIB testicular seminoma.Untreated pure seminoma testis after orchiectomy, clinical IIB, were considered eligible for this prospective observational study. Chemotherapy consisted either four cycles cisplatin etoposide three cisplatin, etoposide, bleomycin.Between April 1994 March 2003, 72 entered onto study at 26 participating centers. Eighteen had disease, 54 disease....
4035 Background: FOLFOX-4 is a standard first-line treatment for patients (pts) with mCRC. The IgG1 monoclonal antibody cetuximab has proven activity in combination cytotoxic chemotherapy. Excellent response rates (RRs) have been reported and FOLFOX-4. This randomized, controlled study was conducted to compare RRs of + vs Methods: Pts previously untreated epidermal growth factor receptor (EGFR)-expressing mCRC not resectable curative intent were eligible. They randomized 1:1, stratified by...
Purpose To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT). Patients Methods Data 523 BM GCT were collected retrospectively 46 centers in 13 countries by using standardized questionnaires. Clinical features correlated overall survival (OS) as the primary end point. Results present at initial diagnosis 228 (group A) relapse 295 B). OS 3 years (3-year OS) was superior group A versus B (48% v 27%; P < .001). Multiple...
// Teodoro Vargas 1 , Juan Moreno-Rubio 2, 3 Jesús Herranz 4 Paloma Cejas 5 Susana Molina Margarita González-Vallinas Marta Mendiola 2 Emilio Burgos 5, 6 Cristina Aguayo 7 Ana B. Custodio Isidro Machado 8 David Ramos 9 Meritxell Gironella 10 Isabel Espinosa-Salinas Ricardo 11 Roberto Martín-Hernández Alberto Risueño 12 Javier De Las Rivas Guillermo Reglero Yaya 13 Carlos Fernández-Martos Jorge Aparicio 14 Joan Maurel 15 Jaime Feliu Ramírez de Molecular Oncology, IMDEA-Food Institute, CEI...
Abstract Background. The need for preoperative chemoradiation or short-course radiation in all T3 rectal tumors is a controversial issue. A multicenter phase II trial was undertaken to evaluate the efficacy and safety of neoadjuvant capecitabine oxaliplatin combined with bevacizumab patients intermediate-risk adenocarcinoma. Methods. We recruited 46 adenocarcinoma selected by magnetic resonance imaging (MRI) who were candidates (R0) resection located middle third clear mesorectal fascia...